Rydex Health Care A holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Rydex Health Care Fund Class A RYHEX
- NAV / 1-Day Return 128.26 / −0.58 %
- Total Assets 21.4M
-
Adj. Expense Ratio
1.640%
- Expense Ratio 1.640%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Health
- Investment Style Mid Value
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 236%
USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 12:11 AM GMT+0
Morningstar’s Analysis RYHEX
Will RYHEX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 24.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 4.54 | 836,485 | Healthcare |
Johnson & Johnson | 3.10 | 570,085 | Healthcare |
UnitedHealth Group Inc | 3.03 | 557,534 | Healthcare |
AbbVie Inc | 2.66 | 488,781 | Healthcare |
Merck & Co Inc | 2.39 | 439,858 | Healthcare |
Thermo Fisher Scientific Inc | 1.93 | 356,085 | Healthcare |
Amgen Inc | 1.80 | 331,065 | Healthcare |
Gilead Sciences Inc | 1.72 | 315,776 | Healthcare |
Pfizer Inc | 1.67 | 307,746 | Healthcare |
Intuitive Surgical Inc | 1.61 | 295,549 | Healthcare |